Case Report

A Case of Etanercept Induced Palmoplantar Pustular Psoriasis


  • Zennure Takçı
  • Gülçin Güler Şimşek
  • Özlem Tekin

J Turk Acad Dermatol 2012;6(3):0-0


Etanercept is a human recombinant soluble tumor necrosis factor  (TNF-α) receptor fusion protein. Etanercept has been used successfully to treat a wide range of inflammatory disorders including psoriasis and psoriatic arthritis resistant to classical disease-modifying treatments. The widespread use of TNF-α antagonists led to the recognition of adverse effects. Herein, we report a case of palmoplantar pustular psoriasis in a 37-year-old man during the etanercept therapy.

Keywords: TNF-α antagonist, etanercept, adverse effect, psoriasis, palmoplantar pustular psoriasis